TTY Biopharm Company Competitors
Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts | Market Cap |
---|---|---|---|---|---|---|---|---|
JNJ | Johnson & Johnson | Outperform |
9
|
$148.95 | $174.55 | 14.13% | 3 | $358.47B |
AZN | AstraZeneca PLC | Outperform |
17
|
£122.64 | £165.99 | 32.70% | 16 | £190.12B |
NOVN | Novartis | Hold |
10
|
CHF90.54 | CHF105.00 | 18.86% | 9 | CHF184.74B |
ABT | Abbott Laboratories | Outperform |
9
|
$104.94 | $118.92 | 20.55% | 7 | $182.56B |
PFE | Pfizer | Outperform |
2
|
$28.27 | $32.87 | 7.89% | 6 | $160.08B |
SAN | Sanofi | Outperform |
16
|
93.08€ | 102.80€ | 17.10% | 9 | 116.22€B |
GSK | GSK | Outperform |
12
|
£17.74 | £17.30 | 9.92% | 12 | £72.32B |
CSL | CSL | Outperform |
12
|
$279.90 | $205.51 | -27.42% | 5 | $135.26B |
BAX | Baxter International Inc | Outperform |
17
|
$35.75 | $44.86 | 23.08% | 5 | $18.22B |
1093 | CSPC Pharmaceutical Group | Buy |
18
|
HK$6.65 | HK$9.50 | 39.85% | 6 | HK$78.77B |
4142 | Adimmune | - |
10
|
NT$31.05 | NT$55.00 | -100.00% | 0 | NT$14.08B |
PSTV | Plus Therapeutics | Buy |
11
|
$2.27 | $11.00 | 560.79% | 2 | $9.71M |